

11th August, 2020

The Manager
BSE Limited
Corporate Relationship Department
P. J. Towers, Dalal Street,
Mumbai – 400 001.

The Manager
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051.

BSE Scrip Code No. 524280

NSE Symbol : KOPRAN

Dear Sir/Madam,

Sub : Outcome of Board Meeting

1. Pursuant to Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are submitting the Board approved Unaudited Standalone and Consolidated Financial Results for the first quarter ended 30th June, 2020 along with Limited Review Report.
2. On the recommendation of the Nomination & Remuneration Committee, the Board has recommended for the approval of the members of the Company at the ensuing Annual General Meeting the re-appointment for a second term of five consecutive years of Dr. Siddhan Subramanian (DIN: 02101174) and Dr. Sunita Banerji (DIN: 02476075) as Independent Directors in compliance with the applicable provisions of the Companies Act, 2013 and the SEBI (LODR) Regulations. If approved by members of the Company, their second term will begin w.e.f. 18th September, 2020 to 17th September, 2025.

Kindly publish the results on your websites.

Brief Profile of the Directors are attached as **Annexure - A**.

The Meeting of the Board of Directors of the Company commenced at 1.00 p.m.

and concluded at 14.25 HH

Regards,

For Kopran Limited



Sunil Sodhani
Company Secretary & Compliance Officer
Membership No. FCS 3897

Encl : As above.

KOPRAN LIMITED

Head Office: Parijat House, 1076, Dr. E. Moses Road, Worli, P. B. No. 9917, Mumbai - 400 018, Maharashtra (India).
Tel.: 9122 4366 1111 • Fax : +9122 2495 0363, 2495 0314 • • Website : www.kopran.com

Annexure - A

Name of the Director	Dr. Siddhan Subramanian	Dr. Sunita Banerji
Director Identification Number	02101174	02476075
Date of Birth	18.03.1951	04.02.1958
Date of Appointment	29 th September, 2014	29 th September, 2014
Qualifications	Phd in Organic Chemistry from Indian Institute of Technology	MBBS
Terms and conditions of appointment & Category	Non-Executive Director (Independent). He is entitled only to receive sitting fees for Board and Committee Meetings	Non-Executive Director (Independent). She is entitled only to receive sitting fees for Board and Committee Meetings
Brief Profile of the Directors	Dr. Siddhan Subramanian has a vast experience covering R&D in chemicals, agrochemicals and colorants, Technical Service in Textiles, Pigments, Paper, Leather, Pharma, Agro and Chemical industries, Sales and Marketing in Pigments, Fine and Life Science Chemicals. Experienced in IPR and worked on SAP and other ERP systems.	Dr. Sunita Banerji received her credentials in obstetrics and gynecology in 1982 after which she set up a successful family Medicine practice in Mumbai in 1989. She has extensive knowledge of pharmaceutical products, especially new products in chronic therapies. She received extensive training in Aesthetics in London and upon her return, she started an Aesthetic Medicine practice.
Relationship with other Directors & KMP's	Not related	Not related

KOPRAN LIMITED

Head Office: Parijat House, 1076, Dr. E. Moses Road, Worli, P. B. No. 9917, Mumbai - 400 018, Maharashtra (India).
Tel.: 9122 4366 1111 • Fax : +9122 2495 0363, 2495 0314 • • Website : www.kopran.com

KOPRAN LIMITED

STATEMENT OF CONSOLIDATED AND STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30TH JUNE, 2020

(Rs. in Lakhs)

Particulars	Consolidated						Standalone					
	For the Quarter ended			For the Year ended			For the Quarter ended			For the Year ended		
	30-06-2020 Unaudited	31-03-2020 Audited	30-06-2019 Unaudited	31-03-2020 Audited	31-03-2020 Audited	31-03-2020 Audited	30-06-2020 Unaudited	31-03-2020 Audited	30-06-2019 Unaudited	31-03-2020 Audited	31-03-2020 Audited	31-03-2020 Audited
(1) Revenue from Operations	12,088.21	8,737.90	8,414.90	35,949.94	35,949.94	3,858.71	5,723.29	3,858.71	3,774.24	3,774.24	17,929.08	17,929.08
(2) Other Income	33.08	17.87	13.25	63.07	63.07	52.00	49.59	52.00	49.71	49.71	199.01	199.01
(3) Foreign exchange gain	318.91	-	234.29	-	-	-	189.90	-	143.22	143.22	-	-
(4) Total Income (1+2+3)	12,440.21	8,755.77	8,662.44	36,013.01	36,013.01	3,910.71	5,962.78	3,910.71	3,967.17	3,967.17	18,128.09	18,128.09
(5) Expenses												
(a) Cost of materials consumed	5,847.77	5,794.08	5,723.10	22,305.58	22,305.58	3,346.20	1,989.27	3,346.20	2,383.91	2,383.91	10,896.12	10,896.12
(b) Purchase of stock-in-trade	-	12.34	152.80	977.51	977.51	12.59	29.13	12.59	202.71	202.71	954.10	954.10
(c) Changes in Inventories of finished goods, stock-in-trade and work-in-progress	1,563.72	(1,511.09)	(635.13)	(2,281.18)	(2,281.18)	(1,703.52)	1,507.26	(1,703.52)	(322.32)	(322.32)	(1,733.34)	(1,733.34)
(d) Employee benefits expense	913.23	877.81	961.53	3,685.21	3,685.21	441.25	456.88	441.25	528.26	528.26	2,002.16	2,002.16
(e) Finance costs	186.10	222.83	209.39	891.17	891.17	147.72	145.74	147.72	133.64	133.64	596.17	596.17
(f) Depreciation and amortisation expense	253.72	239.67	229.83	957.69	957.69	86.64	95.64	86.64	79.80	79.80	347.23	347.23
(g) Other expenses	1,752.04	1,867.48	1,456.49	6,527.49	6,527.49	966.71	896.17	966.71	752.75	752.75	3,467.53	3,467.53
(g) Foreign exchange loss	-	551.50	-	65.76	65.76	-	-	-	-	-	24.86	24.86
Total Expenses (5)	10,516.58	8,054.62	8,098.01	33,129.23	33,129.23	3,652.07	5,120.09	3,652.07	3,758.75	3,758.75	16,554.83	16,554.83
(6) Profit / (Loss) before exceptional items and tax (4-5)	1,923.63	701.15	564.43	2,883.78	2,883.78	258.64	842.69	258.64	208.42	208.42	1,573.26	1,573.26
(7) Exceptional items (Net)	(55.42)	(55.42)	-	(55.42)	(55.42)	-	-	-	-	-	-	-
(8) Profit / (Loss) before tax (6-7)	1,923.63	645.73	564.43	2,828.36	2,828.36	258.64	842.69	258.64	208.42	208.42	1,573.26	1,573.26
(9) Tax expense												
(a) Current Tax	401.77	142.27	118.53	522.33	522.33	62.42	145.26	62.42	38.84	38.84	280.07	280.07
(b) Deferred Tax	98.73	2.08	23.73	183.63	183.63	16.39	95.46	16.39	18.54	18.54	171.21	171.21
(b) Taxation adjustment of earlier years	-	20.38	-	20.38	20.38	-	-	-	-	-	-	-
(10) Profit / (Loss) for the period (8 - 9)	1,423.13	481.00	422.17	2,102.02	2,102.02	179.83	601.96	179.83	151.04	151.04	1,121.98	1,121.98
(11) Other Comprehensive Income												
Items that will not be reclassified to profit and loss												
(a) - Remeasurements of defined benefit plans	(0.48)	33.85	(11.92)	(1.92)	(1.92)	0.40	0.40	29.19	(9.19)	(9.19)	1.62	1.62
Income tax effect on Remeasurement of defined employee benefit plans	0.11	(8.14)	2.56	(0.47)	(0.47)	(0.12)	(0.12)	(8.14)	2.56	2.56	(0.47)	(0.47)
(b) - Net changes in Fair value of investments in equity shares carried at fair value through OCI	-	-	-	-	-	-	-	-	-	-	-	-
Income tax effect on Net changes in Fair value of investments in equity shares carried at fair value through OCI [credit / (charge)]	-	-	-	-	-	-	-	-	-	-	-	-
Items that will be reclassified to profit and loss												
(a) - Exchange difference in translating the financial statements of foreign operation	0.65	13.01	-	20.82	20.82	-	-	-	-	-	-	-
Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
Total Other Comprehensive Income for the period (11)	0.27	38.72	(9.36)	18.43	18.43	0.29	0.29	21.05	(6.63)	(6.63)	1.15	1.15
(12) Total Comprehensive Income for the period (10+11)	1,423.40	519.72	412.81	2,120.45	2,120.45	200.88	602.25	200.88	144.41	144.41	1,123.13	1,123.13



[Handwritten Signature]

(Rs. in Lakhs)

Particulars	Consolidated						Standalone			
	For the Quarter ended			For the Year ended			For the Quarter ended		For the Year ended	
	30-06-2020	31-03-2020	30-06-2019	31-03-2020	31-03-2020	31-03-2020	30-06-2020	31-03-2020	30-06-2019	31-03-2020
Profit for the year attributable to										
- Owners of the Company	1,423.13	481.00	422.17	2,102.02						
- Non - Controlling Interest		-								
Other Comprehensive (Loss) / Income for the year attributable to										
- Owners of the Company	0.27	38.72	(9.36)	18.43						
- Non - Controlling Interest		-								
Total Comprehensive Income for the year attributable to										
- Owners of the Company	1,423.40	519.72	412.81	2,120.45						
- Non - Controlling Interest		-								
(13) Paid-up Equity Share Capital (Face value Rs. 10/- each)	4,324.89	4,324.89	4,324.89	4,324.89	4,324.89	4,324.89	4,324.89	4,324.89	4,324.89	4,324.89
(14) Other Equity				14,643.12						18,642.42
(15) Earnings Per Share (EPS) (Face value Rs. 10/- each)										
(a) Basic	3.29	1.11	0.95	4.86			1.39	0.42	0.33	2.59
(b) Diluted	3.29	1.11	0.95	4.86			1.39	0.42	0.33	2.59

Notes:-

- 1) The above Statement of consolidated and standalone unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act 2013, read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India. There is no minority interest.
- 2) The above Statement of consolidated and standalone unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 11th August, 2020 and have been subjected to limited review by the Statutory Auditors of the Company who have expressed an unmodified conclusion.
- 3) Figures for the quarter ended March 31, 2020 represents the balancing figures between the audited figures for the full financial year and the published year to date reviewed figures upto third quarter of the financial year ended March 31, 2020.
- 4) The Company is engaged primarily in the Pharmaceuticals business and there are no separate reportable segments as per Ind AS 108 on "Operating Segment Reporting".
- 5) The Group has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the Group will continue to closely monitor for any material changes to future economic conditions.
- 6) Figures for the previous period have been regrouped or reclassified, wherever necessary to make them comparable with the figures of the current period.

FOR KOPRAN LIMITED



Surendra Somani
Executive Vice Chairman



Place : Mumbai

Date : 11th August, 2020

**Independent Auditor's Review Report on Quarterly Unaudited Standalone
Financial Results of Kopran Limited Pursuant to the Regulation 33 of the
Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015, as amended**

**To the Board of Directors of
Kopran Limited**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Kopran Limited, ("the Company") for the quarter ended June 30, 2020 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. CHARTERED ACCOUNTANTS

Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KHANDELWAL JAIN & CO.

Chartered Accountants,

Firm Registration No.: 105049W



(S. S. SHAH)

PARTNER

Membership No.: 33632

UDIN : 20033632 AAABE1965



Place: Mumbai

Date : August 11, 2020

**Independent Auditor's Review Report on Quarterly Unaudited Consolidated
Financial Results of Kopran Limited Pursuant to the Regulation 33 of the
Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015, as amended.**

**To the Board of Directors of
Kopran Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Kopran Limited ("the Parent" or "the Company") and its subsidiaries (the parent and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2020 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard - 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, the Circular and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following subsidiaries:

- Kopran Research Laboratories Limited
- Kopran Lifesciences Limited
- Kopran (H. K) Limited
- Kopran (UK) Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6(a) We did not review the interim financial information of 2 subsidiaries included in the consolidated unaudited financial results, whose interim financial information, before consolidated adjustments, reflect total revenues of Rs. 6,623.19 Lakhs, total net profit after tax of Rs. 717.46 Lakhs and total comprehensive income of Rs. 716.80 Lakhs for the quarter ended June 30, 2020 as considered in the consolidated unaudited financial results. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.



6(b) The consolidated unaudited financial results includes the interim financial information of 2 subsidiaries which have not been reviewed by their auditors, whose interim financial information, before consolidated adjustments, reflect total revenue of Rs. NIL, total net loss after tax of Rs. 1.50 Lakhs and total comprehensive loss of Rs. 1.46 Lakhs for the quarter ended June 30, 2020 as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For **KHANDELWAL JAIN & CO.**

Chartered Accountants,

Firm Registration No.: 105049W



(S. S. SHAH)

PARTNER

Membership No.: 33632

UDIN : 20033632 A A A B F 8515



Place: Mumbai

Date : August 11, 2020